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To the Editor: Tsai and Lian [1] and Furlan et al [2]
Reply from the Authorindependently demonstrated that a deficiency in the activ-
Deficiency of von Willebrand factor-cleaving proteaseity of von Willebrand factor-cleaving metalloprotease,
(ADAMTS-13) activity should not be considered the soleADAMTS-13 or the presence of its inhibitory antibodies
criterion for administering plasma therapy to patients withcauses thrombotic thrombocytopenic purpura. It is un-
thrombotic microangiopathies (TMA). Actually most pa-known whether a similar mechanism occurs in patients
tients with different forms of TMA, including geneticwho develop thrombotic microangiopathy (TMA) follow-
forms associated with factor H deficiency, referred to theing organ transplantation. We have recently shown that
Italian Registry for Recurrent and Familial hemolytic ure-the ADAMTS-13 activity was undetectable in plasma
mic syndrome (HUS) and thrombotic thrombocytopenicsamples obtained from a patient who developed TMA
purpura (TTP) responded to plasma therapy [1], regard-after receiving a cadaveric renal allograft. Deficiency of
less of ADAMTS-13 activity. Thus, restricting plasma in-the protease enzyme occurred in the presence of its inhibi-
fusion or exchange to cases with congenital or acquiredtory antibodies. Discontinuation of cyclosporine and daily
deficiency of ADAMTS-13 activity would deprive someplasma exchange raised the ADAMTS-13 activity, fol-
TMA patients of the only potentially effective treatment.
lowed by resolution of the microangiopathic hemolysis
Moreover, assays of ADAMTS-13 activity are lengthy
and improvement of the graft function [3]. and available only in specialized reference laboratories.
Ruggeneti [4] pointed out in an article recently pub- Thus, plasma therapy should be decided on the basis of
lished in Kidney International that restoration of von clinicopathologic observations [2]. Samples for later de-
Willebrand factor-cleaving protease activity in parallel termination of ADAMTS-13 activity could be collected
with disease remission does not necessarily imply that before plasma therapy is started. The activity level may
normalization of the protease activity is the determinant influence subsequent therapeutic decisions [3]. Sporadic
of response to plasma. We are curious if this is based forms, including posttransplant TMA, are often precipi-
on case studies or solely speculations. In our case, we tated by drugs. In these forms, drug discontinuation and
showed that the ADAMTS-13 activity rapidly increased plasma exchange usually rise ADAMTS-13 activity and
to 50% or higher after two sessions of plasmapheresis. remove the inhibitors. In recurrent forms with congenital
We further showed that the immunoglobulin G (IgG) ADAMTS-13 deficiency, plasma induces disease remis-
molecules isolated from the patient’s plasma inhibited sion even before, or without, normalizing ADAMTS-13
the ADAMTS-13 activity in normal plasma. During activity [4]. In forms with continuous formation of the
disease remission, the IgG molecules isolated from the inhibitor, we and others have seen that the antibody titer
patient’s plasma showed no inhibitory effect on the decreases immediately after treatment, but returns to
ADAMTS-13 activity in normal plasma. We speculate pretreatment values shortly after stopping plasma, after
in cases that do not recur [4].that plasma exchange confers its effectiveness by replen-
